# Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib

> **NCT00979966** · PHASE2 · COMPLETED · sponsor: **Central European Society for Anticancer Drug Research** · enrollment: 22 (actual)

## Conditions studied

- Non-clear Cell Renal Cell Cancer

## Interventions

- **DRUG:** Temsirolimus
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT00979966
- **Lead sponsor:** Central European Society for Anticancer Drug Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2012-07
- **Final completion:** —
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2012-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00979966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00979966, "Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00979966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*